=Vanda Pharmaceuticals (VNDA) receives negative opinion from CHMP

Vanda Pharma receives negative opinion from CHMP against the marketing authorization of Fanaptum :

The European Medicines Agency's Committee for Medicinal Product for Human Use (CHMP) has adopted a negative opinion recommending against the marketing authorization of Fanaptum (oral iloperidone tablets) for the treatment of schizophrenia in adult patients in the European Union.

• The CHMP was of the opinion that the benefits of Fanaptum did not outweigh its risks and recommended against marketing authorization.
• Vanda intends to appeal this opinion and request a re-examination by the CHMP.